[Neoadjuvant treatment with cisplatin, 5-FU and folinic acid in advanced head and neck cancer].
From May to February 1992, 32 patients diagnosed as advanced cancer of the head and neck were included in a program of neoadjuvant treatment with cisplatin, 5-FU, and folinic acid, followed by radiotherapy (45 at 70 Gy) and/or surgery. Twenty patients were considered fully evaluable; their global response rate was 75% (7 complete responses and 8 partial responses). Five patients had no appreciable response or progression. Radiotherapy after chemotherapy enhanced the response, yielding complete responses in 4 patients and partial response in 1. Toxicity was moderate, except for mucositis (9 cases grade 3-4), despite high doses of drugs and radiotherapy. Given the clinical results, this combination may be promising as a first-line treatment against advanced cancer of the head and neck.
Contreras
J
J
Servicio de Oncología Radioterápica, Hospital Regional de Málaga.
Medina
J A
JA
Albero
A
A
Herruzo
I
I
Marina
E
E
Azcoaga
J M
JM
Bretón
J J
JJ
D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D005472:Fluorouracil / Q000008:administration & dosage / Q000627:therapeutic use*; D006258:Head and Neck Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage / Q000627:therapeutic use*; D008875:Middle Aged; D009367:Neoplasm Staging; D015996:Survival Rate
D002945:Cisplatin; D002955:Leucovorin; D005472:Fluorouracil
Tratamiento neoadyuvante en el cáncer avanzado de cabeza y cuello con cisplatino, 5-fluorouracilo y ácido folínico.